Actively Recruiting
Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-02-10
150
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Massive blood loss occurs in metastatic spinal tumor resection and may cause severe complications. The objective of this study is to investigate whether the use of tranexamic acid will reduce perioperative and postoperative bleeding when compared to those without use of tranexamic acid.
CONDITIONS
Official Title
Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed as metastatic carcinoma of the thoracolumbar spine
- Solitary neoplasm involving only one segment of spine
- Patients undergoing separation surgery
You will not qualify if you...
- Abnormal coagulation function before surgery
- Allergy to tranexamic acid
- Neoplasm involving more than one segment of spine
- Patients with rich blood supply who need embolization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 311200
Actively Recruiting
Research Team
H
Hengyuan Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here